SCHEMBL7783144

SCHEMBL7783144

CCCOc1ccc(CCNCCNc2cc(C)nc3c2c2ccccc2n3-c2c(C)cc(C)cc2C)cc1OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.40
ABCB1 P08183 1/20 0.38
NPY1R P25929 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
ADRB2 P07550 2/20 0.38
DRD2 P14416 1/20 0.38
DRD1 P21728 1/20 0.38
DRD4 P21917 1/20 0.38
DRD3 P35462 1/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 2/20 0.37
LMNA P02545 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
OXTR P30559 1/20 0.37
AVPR1A P37288 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7791107 0.88 SMPD1 (0.44) ABCB1RXFP1HPGDMEN1KMT2A
SCHEMBL7783151 0.87 HSD17B10 (0.43) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL7783150 0.86 RECQL (0.38) ABCB1NPY1RRXFP1PKMHPGD
SCHEMBL7788159 0.85 NPY1R (0.52) ABCB1NPY1RRXFP1MEN1KMT2A
SCHEMBL7791102 0.84 SIGMAR1 (0.40) SIGMAR1ABCB1RXFP1ADRB2DRD2
SCHEMBL7792988 0.81 MAPT (0.48) RXFP1MEN1KMT2AMAPTLMNA
SCHEMBL7676276 0.78 CRHR1 (0.49) RXFP1HPGDMEN1KMT2AALDH1A1
SCHEMBL7788905 0.76 NPY1R (0.49) ABCB1NPY1RRXFP1MEN1KMT2A
SCHEMBL7783167 0.75 TP53 (0.39) MAPTTP53
SCHEMBL5793689 0.74 USP2 (0.44) NPY1RPKMHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6221875-B1 TREATING FEEDING DISORDERS, OBESITY, BULIMIA NERVOSA OR HYPERTENSION IN A MAMMAL NEUROGEN CORPORATION 2001-04-24 US claimed
US-20010031758-A1 Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands NEUROGEN CORPORATION 2001-10-18 US disclosed
US-6221875-B1 TREATING FEEDING DISORDERS, OBESITY, BULIMIA NERVOSA OR HYPERTENSION IN A MAMMAL NEUROGEN CORPORATION 2001-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031758-A1 Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands NPY1R, NPY2R, NPY5R SIGMAR1 211/4885ABCB1 3180/4885NPY1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.